Search results
Results from the WOW.Com Content Network
Common side effects include nausea, diarrhea, constipation, headache, rash, and pain at the site of injection. [3] Serious side effects include Clostridioides difficile infection, seizures, and allergic reactions including anaphylaxis. [3] Those who are allergic to other β-lactam antibiotics are more likely to be allergic to meropenem as well. [3]
Reported side effects include injection site reactions, rash, and rarely toxic epidermal necrolysis. Gastrointestinal side effects generally include diarrhea and nausea and vomiting. Although C. difficile infection is a possible complication of aztreonam therapy, this antibiotic is associated with a low risk of developing C. difficile infection ...
Severe side effects may include anaphylaxis, seizures, and Clostridioides difficile-associated diarrhea. [4] It is unclear if use during pregnancy is safe. [5] Meropenem works by blocking the construction of the bacterial cell wall while vaborbactam blocks the breakdown of meropenem by some beta-lactamases. [4]
A new study found that some medications could have the unintended benefit of reducing dementia risk, while others could increase the risk. A doctor comments on the findings.
The new drug is intended for treatment of moderate to severe acute pain in adults. ... The most common side effects of Journavx, according to the company’s website, include itching, muscle ...
The β-lactam core structures. (A) A penam.(B) A carbapenam.(C) An oxapenam.(D) A penem.(E) A carbapenem.(F) A monobactam.(G) A cephem.(H) A carbacephem.(I) An oxacephem. This is a list of common β-lactam antibiotics—both administered drugs and those not in clinical use—organized by structural class.
For this study, researchers analyzed medical data from almost 394,000 adults 40 years and older with type 2 diabetes and active COPD that were taking GLP-1, SGLT-2, or DPP-4i medications.
The carbapenems imipenem and meropenem are recommended by the American Thoracic Society and the Infectious Disease Society of America as one of several first-line therapy options for people with late-onset hospital-acquired or ventilator-associated pneumonia, especially when Pseudomonas, Acinetobacter, or extended spectrum beta-lactamase ...